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Abstract
Background: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) 
that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism 
pathways.
Methods: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on 
the basis of previous studies showing that they had preferential specificity for certain cancers. Sera examined were 
from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal 
CTs (35); and normal non-smokers (36). Logistic regression models based on the antibody biomarker levels among the 
high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer 
in these cohorts.
Results: Statistically significant differences in the distributions of each of the biomarkers were identified among all five 
groups. Using Receiver Operating Characteristic (ROC) curves based on age, c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, 
and survivin, we obtained a sensitivity = 81% and specificity = 97% for the classification of cancer vs smokers(no 
nodules, solid nodules, or GGO) and correctly predicted 31/36 healthy controls as noncancer.
Conclusion: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers 
with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.
Background
Early detection of lung cancer is critical for impacting the
poor 5-year survival of 15 percent that has persisted for
decades. If the cancer is detected in Stage I, survival can
exceed 80 percent [1]. CT scans of the chest have greater
sensitivity compared to posterior-anterior chest x-rays in
detecting small non-calcified nodules that may represent
early lung cancers; however, this technique has poor
specificity because of the high prevalence of non-calcified
and ground glass pulmonary nodules [2,3]. These nodules
may be due to granulomatous disease, fibrosis, atypical
adenomatous hyperplasia (AAH), bronchoalveolar carci-
noma (BAC), adenocarcinoma, or slowly resolving
inflammatory lesions. Ground glass opacities are hazy
nodules without obscuration of underlying vascular
markings. The National Lung Cancer Screening Trial has
been undertaken by the National Institutes of Health to
test the hypothesis that CT-scan screening reduces mor-
tality by increased detection of Stage I and II lung can-
cers.
Blood tests such as serum autoantibodies may identify
individuals with early lung cancer and distinguish high-
risk smokers with benign noncalcified lesions from those
with lung cancer. Malignant cells can activate both the
cellular and humoral immune systems, leading to autoim-
munity to autologous cellular antigens. Autoantibodies to
p53, a tumor suppressor protein mutated in 70% of smok-
ers' lung cancer, were detected in the serum of patients
with breast cancer in 1982 [4]. The NHLBI Lung Health
Study had 23 cancers in the 5-year trial and 5 (23%) had
p53 autoantibodies including sera from 2 lung cancers
drawn 6 and 7 months prior to diagnosis [5]. In 133 lung
cancer patients, antibodies to p53 were detected in 25
(18.8%), with significant associations with squamous cell
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type, smoking, and advanced stage [6], and a similar study
found p53 autoantibodies in 17.9% of heavy smokers with
lung cancer [7]. Five percent of NSCLC sera contained
antibodies to c-myc, p53, and eukaryotic translation initi-
ation factor 4 G (eIF4G) [8]. Antibodies with specificity
for antigens initially recognized by cytotoxic T lympho-
cytes, e.g. MAGE, tyrosinase, and NY-ESO-1 have been
found in few lung cancer sera [9]. Other immunogenic
tumor -associated antigens (T AAs) ha ve been identified
through the use of autoantibodies in cancer sera to
immunoscreen cDNA expression libraries in order to
identify cDNA clones encoding those TAAs [10-12].
Most of these TAAs are involved in cellular functions,
including DNA replication and transcription, and pre-
messenger RNA splicing and translation [12]. TAAs are
often membrane receptors such as HER-2/neu oncopro-
tein, tumor suppressor gene proteins, cell cycle associ-
ated proteins (cyclin B1), centromere protein F (CENP-
F), or onconeural antigens [13,14]. Autoantibodies to
some of these antigens have been found in patients with
breast, hepatocellular, ovarian, neuroendocrine, colorec-
tal and lung cancers [4,15-19]. A proteomic approach
using solubilized proteins from lung adenocarcinoma cell
line A549 and lung tumors were subjected to two-dimen-
sional PAGE followed by Western blot analysis in which
individual sera were tested for antibodies [20]. Glycosy-
lated Annexin I was detected in 12/30 (40%) of lung ade-
nocarcinomas and 3/18 squamous cell carcinomas but
none in 51 healthy subjects; Annexin II was similar but
was more specific for lung cancer. Annexin I is expressed
in bronchial epithelium and Annexin II is found in type I
and II alveolar epithelial cells. Another autoantibody
referred to as PGP 9.5, an ubiquitin COOH-terminal
hydrolase, was also detected in 9/64 lung cancer patients
and as an antigen in 2 more [21]. Chapman and col-
leagues recently showed that screening for antibodies in
lung cancer using a panel of seven TAAs, p53, c-myc,
HER2, NY-ESO-1, CAGE, MUC1, and GBU4-5, resulted
in a sensitivity of 76% and specificity of 92% [22].
We hypothesized that cumulative reactivity to a
selected panel of TAAs would distinguish individuals
with lung cancer from those with benign pulmonary nod-
ules, and ground glass opacities caused by inflammation,
fibrosisor neoplasia [23]. Using a mini-array of TAAs (c-
myc, p53, cyclin B1, p62, Koc, IMP1 and survivin), we
previously showed a greatly increased frequency of posi-
tive immune reactivity in breast, lung, prostate, gastric,
colorectal and hepatocellular carcinoma [23-26]. Our
goal was to develop a panel of T AAs to guide CT scan
screening of high risk smokers who have noncalcified
nodules to determine whether they are at risk for lung
cancer.
Methods
Study population
One hundred and fifty eight high risk tobacco smokers
and asbestos-exposed individuals in the New York Uni-
versity Lung Cancer Biomarker Center (NYU LCBC)
were evaluated with CT-scans, questionnaires, blood and
pulmonary function tests at the time of entry into the
cohort. They were recruited from a public utility union
where they had asbestos exposure in power plants, and
faculty referrals for smokers with age >50 years and >20
pack-years of smoking. Based on these CT scans, the
NYU participants were classified into the following
groups: no nodules (n = 35), solid nodules (n = 55), and
ground glass opacities (GGO, n = 46). An additional
group of 22 lung cancer cases were identified upon refer-
ral through a thoracic surgeon; phlebotomy was per-
formed on the day of surgery and stage and histology
performed during the hospitalization. A fifth group of 36
healthy non-smokers were enrolled at the Scripps Gen-
eral Clinical Research Center. The Scripps group was
used as normal controls in this study and came from a
pool of blood donors who were employees of the Scripps
Medical Institutions in La Jolla, California. They were
identified to be HIV-negative and to have no evidence of
HBV or HCV infection. The median age and gender are
shown in Tables 1 and 2. This group of normal, non-
smoking controls are a portion of a larger pool of donors
available to investigators with IRB approval for their stud-
ies.
All participants in the NYU LCBC were administered a
questionnaire including questions on medical history,
occupational exposures, family history and respiratory
symptoms. Spirometry was performed according to ATS
criteria. Low dose chest CT using a multidetector scan-
ner (16 detectors) was performed as described previously
[3]. Follow-up scans were performed at defined intervals
based on the initial CT scan findings. CT scans were
reviewed by a radiologist and a pulmonologist. All study
subjects signed an informed consent and the protocol
was approved by the NYU School of Medicine Human
Subjects Review Committee.
Measurement of Immune Reactivity to TAAs
From previous studies [16,19,26], ten TAAs were selected
to form a panel of TAAs for determining presence or
absence of autoantibodies in each serum specimen. The
TAAs consisted of purified full-length recombinant pro-
teins: three insulin-like growth factor 2 mRNA binding
proteins (IMP1, p62/IMP2 and koc/IMP3), p53, c-myc,
cyclin A, cyclin B1, cyclin D1, CDK2 and survivin.
Purification of recombinant TAAs and enzyme-linked
immunosorbent assay was performed as previouslyRom et al. BMC Cancer 2010, 10:234
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described using protein denaturing technologies
[16,19,27]. Briefly, we subcloned p62 cDNA into the
pET28a vector, producing a fusion protein with NH-ter-
minal 6 × histidine and T7 epitope tags. The recombinant
protein was affinity purified on nickel-nitrilotriacetic acid
(Ni-NTA) columns according to the manufacturer's
instructions (Qiagen, Inc., Valencia, CA, USA). IMP3/
Koc cDNA cloned in the pcDNA3 vector was similarly
subcloned into the pET28a vector and the recombinant
protein was expressed as above. IMP1 construct,
pCMV5-IMP1, was kindly provided by Dr F.C. Nielsen
(University of Copenhagen, Copenhagen, Denmark), and
p53 clone, p53SN3, by Dr Y. Yin (Columbia University,
New York, NY). cDNA from c-myc was amplified by
polymerase chain reaction from fetal liver tissue and sur-
vivin cDNA from human survivin EST clone (BG25843)
before subcloning in the pET28a vector. Glutathione-S-
transferase (GST)-cyclin D1 fusion protein was prepared
from plasmid Gex (pGEX) containing cyclin D1 coding
region obtained by amplification with polymerase chain
reaction. CDK2 protein was from plasmid pRK171 con-
taining PCR-amplified coding region of CDK2. CyclinB1
without a fusion protein partner was prepared from
pRK171 expressing cyclin B1 and was a gift from C.
McGowan (The Scripps Research Institute, La Jolla, CA)
and pGEX expressing cyclin B1 with GST fusion partner
was a gift from E. Harlow (Massachusetts General Hospi-
tal Cancer Center, Boston, MA). pRSET expressing cyclin
A was a gift from T. Hunter (Salk Institute, La Jolla, CA)
[16]. To produce recombinant p90, gel purified 1.2 kb
EcoR1-XhoI insert from GC291 was excised from the
pBK-CMV plasmid and subcloned into the pET28b
expression vector (Novagen, Madison, WI) as previously
described [28]. The pET construct was transformed into
E. coli BL21 (DE3) (Stratagene, La Jolla, CA) for recombi-
nant protein expression in the presence of 2 mM IPTG.
After a four-hour incubation, recombinant proteins were
extracted and purified using nickel-nitrilotriacetic acid
(Ni-NTA) bead affinity columns (Qiagen, Valencia, VA)
[25].
Enzyme-linked immunosorbent assay (ELISA) was per-
formed as previously described [25]. Purified recombi-
nant proteins were diluted in phosphate buffered saline
(PBS) to a concentration of 0.5 micrograms/ml for coat-
ing wells of microtiter plates. Human sera diluted at 1:200
were incubated in the antigen-coated wells. Horseradish
peroxidase-conjugated goat anti-human IgG (Caltag Lab-
oratories, San Francisco, CA) was added and 2,2'-axino-
bis (3-ethylbenzthiazoline-6-sulfonic acid) (Boehringer
Mannheim GmbH, Mannheim, Germany) was used as
the substrate. Each sample was assessed in duplicate, and
the average value at 490 nm was used for data analysis.
Statistical Analysis
The objectives of this study were to distinguish lung can-
cer from other groups based on TAA levels, to compare
the distributions of TAA levels among the groups, and to
predict the presence of cancer based on these ten bio-
markers.
The distributions of demographic and medical history
characteristics were summarized for the five groups of
subjects under study using frequency distributions for
categorical variables and summary statistics for continu-
ous variables. For each group of samples, descriptive
summary statistics (mean, median, and standard devia-
tion) and box plots are provided for each of the 10 bio-
markers under study.
Kruskal-Wallis nonparametric analysis of variance Chi
Square tests were used to assess the differences in the dis-
tributions of individual biomarker measurements by clas-
sification group. These analyses were conducted to
compare the four groups of lung cancer patients, GGOs,
solid nodules, and nodules and for all five groups of sub-
jects including the healthy controls. If the overall test sta-
Table 1: Study Subject Characteristics by Classification Group.
Group Control
(N = 36)
No Nodules
(N = 35)
Solid Nodules
(N = 55)
GGO
(N = 46)
Cancer
(N = 22)
AGE (years) Median 55.5 56 59 56 64.5
P a c k  Y e a r s M e d i a n N A4 33 94 55 2
Asbestos Yrs Median NA 25 18 12.5 0
FEV1/FVC Median NA 71 75 73.5 68.5
Years Follow 
Up
Median NA NA 3.0 2.5 NARom et al. BMC Cancer 2010, 10:234
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Table 2: Study Subject Medical Characteristics by Classification Group.
Group Control
# (%)
36(100%)
No Nodules
# (%)
35(100%)
Solid Nodules
# (%)
55(100%)
GGO
# (%)
46(100%)
Cancer
# (%)
22(100%)
Male 16(44.4%) 15(42.9%) 22(40%) 18(39.1%) 11(50%)
Female 20(55.6%) 20(57.1%) 33(60%) 28(60.9%) 11(50%)
Cancer on follow up NA 0(0%) 0(0%) 5(10.9%) 0(0%)
SN or GGO Resolved NA 0(0%) 5(9.1%) 6(13%) 0(0%)
Emphysema on CT NA 11(31.4%) 17(30.9%) 21(45.7%) 9(40.9%)
Pleural Plaque(s) NA 2(5.7%) 6(10.9%) 3(6.5%) 0(0%)
Fibrosis NA 2(5.7%) 3(5.5%) 2(4.3%) 0(0%)
Diabetes NA 3(8.6%) 8(14.5%) 5(10.9%) 2(9.1%)
Rheumatoid 
Arthritis
NA 0(0%) 2(3.6%) 1(2.2%) 1(4.5%)
Lupus NA 0(0%) 0(0%) 0(0%) 1(4.5%)
IBD NA 0(0%) 1(1.8%) 1(2.2%) 1(4.5%)
Psoriasis NA 0(0%) 2(3.6%) 1(2.2%) 0(0%)
HIV NA 0(0%) 0(0%) 1(2.2%) 0(0%)
Thyroid Disease NA 2(5.7%) 8(14.5%) 6(13%) 3(13.6%)
Hepatitis NA 1(2.9%) 2(3.6%) 4(8.7%) 1(4.5%)
Bronchiectasis NA 0(0%) 4(7.3%) 3(6.5%) 1(4.5%)
Bronchiolitis NA 0(0%) 2(3.6%) 3(6.5%) 0(0%)
Diffuse Nodular 
Disease
NA 0(0%) 2(3.6%) 2(4.3%) 0(0%)
Pneumonia NA 0(0%) 0(0%) 3(6.5%) 0(0%)
Possible concurrent 
malignancy
NA 0(0%) 3(5.5%) 3(6.5%) 2(9.1%)Rom et al. BMC Cancer 2010, 10:234
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tistic is significant (p ≤ 0.05, 2 -sided) for an individual
biomarker, then pairwise Wilcoxon Rank Sum tests were
used to identify the groups that are significantly different
in their distributions of an individual TAA. A conserva-
tive Bonferroni adjustment for multiple testing was used
for the analysis of each biomarker; no adjustment was
used for the examination of the 10 biomarkers. Logistic
regression models were developed to examine the predic-
tion of group membership based on the individual bio-
markers and combinations of biomarkers. Since the
control group was from a different population (healthy,
nonsmokers), we considered only the 158 subjects from
the 4 groups in the NYU cohorts (lung cancers, GGO,
solid nodule, and no nodules) in the analysis. Box Cox
transformations were considered for the biomarker mea-
surements and log transformations were selected for the
regression analyses. Model fit was evaluated using the
Akaike Information Criterion (AIC) with model selection
based on minimizing the AIC. Two sets of multiple logis-
tic regression models were considered. First, we used the
logistic regression models to predict the presence or
absence of cancer at the initial screening (combining the
no nodules, solid nodules and ground glass opacity
groups); second, we considered ground glass opacities vs.
no ground glass opacities (combining the no nodules,
solid nodules and cancer groups). The control group of
healthy volunteers that was not included was used as a
test set to evaluate the predictive ability of the models.
Receiver Operating Characteristic (ROC) curves were
created to plot sensitivity and specificity of the selected
models for each outcome. All computations were per-
formed using SPlus, SAS, and R.
Results
The characteristics of the subjects enrolled in the five
groups are shown in Table 1. We noted that the lung can-
cer patients were older (median age 64.5) compared with
other subjects and had increased pack years of smoking
(52) compared with other subjects; these lung cancer
cases also had the lowest median FEV1/FVC (68.5). Gen-
der and median pack-years smoking were comparable
among the four smoking groups. The lung cancer
patients tended to have slightly lower FEV 1/FVC ratios
compared with individuals without known cancer (lung
cancer median 68.5% vs. smokers with normal CTs 71 ±
8%). Table 2 provides a summary of medical history for
these groups of subjects. The nonsmoking controls had
been screened to be in good health. Note that 5 (10.9%)
subjects with ground glass opacities developed lung can-
cer on follow-up (13% resolved); 9.1% of patients with
solid nodules also had resolution of these nodules on fol-
low up (Table 2). Only the proportion of patients with
emphysema and pneumonia differed among the groups
with the highest proportions with these diseases on CT
scan observed in the ground glass group (p ≤ 0.001, p =
0.04, respectively, chi square tests).
All of the patients with lung cancer and most of the
individuals with ground glass opacities demonstrated
reactivity to one or more of the 10 TAAs, (using a cut-off
value of > mean + 3 SD of non-smoking normal sera). Fig-
ure 1 provides box plots that summarize the distributions
of age and of autoantibodies to each of the 10 TAAs for
the five groups of subjects. The distributions of each of
the 10 biomarkers differed among the five classification
groups (p = 0.008 for cyclinB1; p < 0.001 for all others).
After a conservative adjustment for multiple compari-
sons, we note that the healthy nonsmoking controls have
significantly lower median levels of each of these bio-
markers compared with the four groups of smokers
including lung cancer cases. Table 3 summarizes the
results of the pairwise Wilcoxon Rank Sum tests (bolded
values are significant with a conservative Bonferroni
adjustment for multiple testing) for the comparisons
among the four groups of subjects in the NYU cohorts. In
particular, the median levels of autoantibodies to Cyclin
A, Cyclin D1, and survivin are lower in the group with
ground glass opacities compared with the groups with
cancer, no nodules, or solid nodules. The cancer group
has significantly higher levels of autoantibodies to c-myc,
Cyclin A, and CDK2 compared to the solid nodule group.
One hundred forty nine of the 158 high-risk smokers
and cancer cases had complete data on all 10 biomarkers.
A multiple logistic model to predict cancer versus no can-
cer (no nodules, solid nodules, or ground glass opacities)
yielded an AIC of 86.6 with 91% accuracy using 10 fold
cross validation (Table A4A). The best stepwise model
reduced the AIC to 79.4 with the same cross validation
prediction accuracy (Table B4B). C-myc, cyclin A, cyclin
B1, cyclin D1, CDK2, and survivin contributed to the sep-
aration between the cancer and non cancer groups. The
resulting Receiver Operating Characteristic (ROC) curve
is shown in Figure 2 along with the sensitivity and speci-
ficity associated with the optimal cutpoint (91%, 99%
r es pect i v e l y ) .  W h e n  t h is  m od e l ,  w h i c h  i n c l u d e s  c - m y c,
cyclin A, cyclin B1, cyclin D1, CDK2, and survivin, was
applied to the healthy non-smoking control group as a
test set, we correctly classified 31/36 control patients as
non-cancer using a cutoff value of 0.085 which maximizes
the sensitivity and specificity of the logistic function at
81% and 97% respectively. Removal of outliers yielded
similar results.
Discussion and Conclusions
A biomarker for the early detection of lung cancer will
likely require a panel of 4-10 markers to maximize sensi-
tivity and specificity. High throughput technological
advances allow for the rapid evaluation of a huge number
of possible markers, for example, by microarray analysisRom et al. BMC Cancer 2010, 10:234
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of gene expression, or proteomic analysis using SELDI or
MALDI technology. 2 D-PAGE has identified antioxidant
enzymes, ATP synthases, β1,4-galatosyltransferase, gluta-
thione-S-transferase, and ubiquitin thiolesterase among
others to be increased up to 10-fold in lung cancer com-
pared to uninvolved tissue and correlated with their gene
expression [29]. Elevated levels of phosphoglycerate
kinase 1 in the serum were significantly correlated with
poor outcome in lung adenocarcinoma [30]. Protein
expression profiling using MALDI-TOF of lung adeno-
carcinoma has identified unique peaks that were
sequenced and found to match macrophage migration
inhibitory factor and cyclophilin A that also were over-
expressed in tumor tissue using immunohistochemistry
[31]. In contrast, using tissue microarrays and immuno-
histochemistry for these two proteins in 234 lung cancer
patients, Howard and colleagues found no correlation
with outcome although both proteins were over-
expressed in most NSCLC tumors [32]. We identified 7 of
84 antibodies using two-color rolling-circle amplification
protein microarrays that gave a significant (p < 0.01) dif-
ference for 24 lung cancer patients compared to 24 con-
trols and 32 COPD subjects [33]. Proteins identified were
C-reactive protein, serum amyloid A, mucin 1, and α-1-
antitrypsin. C- Reactive Protein and Serum Amyloid A
may reflect the inflammatory milieu surrounding the
lung tumor, or may reflect over-production of these as
actual biomarkers. C-Reactive Protein along with lung
function and pack-years of smoking predict progression
of bronchial dysplastic lesions [34]. Recently 14-3-3
Theta and LAMR1 were added to Annexin I and PGP 9.5
achieving a ROC of 0.73 (0.69 to 0.81) with significant p
values for three out of four autoantibodies comparing the
samples drawn at 0-6 months to 7-12 months prior to
diagnosis in 85 lung cancer and control paired samples
from the Carotene and Retinol Efficacy Trial serum bank
[35].
Zhong and colleagues used fluorescent microarray
technology to identify immunogenic phage-expressed
proteins from T7 phage NSCLC tumor libraries, and to
assess the presence of corresponding antibodies in the
plasma of patients with NSCLC [36,37]. Their five most
predictive phage-expressed proteins, combined in a logis-
tic regression analysis, achieved 90 percent sensitivity
and 95 percent specificity in their population of advanced
stage NSCLC. The leave-one-out statistical analysis
achieved 88.9 percent diagnostic accuracy. A subsequent
study using similar antibody profiling in patients with
early stage lung cancer from a CT screening study identi-
fied a slightly different panel of five antibody markers that
was able to correctly classify stage I NSCLC with 91 per-
cent accuracy, and predicted the presence of lung cancer
up to five years before diagnosis with a sensitivity of
almost 83 percent [18]. However, this panel of markers
did not perform as well in identifying bronchoalveolar
cell carcinoma. Proteins of interest were the heat shock
proteins, proto-oncogenes, ras-associated oncogene,
transcriptional regulators, DNA mismatch repair, tumor
necrosis factor receptor, paxillin (focal adhesion protein),
and several unknown proteins. Plakophilin 3 and ubiqui-
l i n  1  h a v e  bee n  f o u n d  t o  be  h u m o r a l  r e s po n se  t a r g e ts
using lung cancer phage display libraries [38,39]. Serum
Table 3: Pairwise non-parametric Wilcoxon tests with Bonferroni adjustment to detect differences between classification 
groups and biomarker levels (comparisons to controls not shown)
p53 c-myc imp1 p62 imp3 cycA cycB1 cycD1 cdk2 survivin
No 
Nodules
Solid 
Nodules
1.000 0.031 1.000 0.001 1.000 1.000 0.228 0.351 1.000 0.022
No 
Nodules
GGO 0.750 0.810 0.128 1.000 0.680 <0.001 1.000 <0.001 1.000 <0.001
No 
Nodules
Cancer 0.630 0.049 1.000 1.000 1.000 0.258 1.000 0.001 0.025 1.000
Solid 
Nodules
GGO 0.500 <0.001 <0.001 1.000 0.170 0.003 0.007 <0.001 0.423 <0.001
Solid 
Nodules
Cancer 0.630 <0.001 0.009 1.000 1.000 <0.001 1.000 0.018 0.001 0.139
GGO Cancer 1.000 0.532 1.000 1.000 0.350 <0.001 1.000 <0.001 0.262 <0.001Rom et al. BMC Cancer 2010, 10:234
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tumor markers such as carcinoembryonic antigen have
been reported to be positive in 46 percent of 200 lung
adenocarcinoma patients, as well as CA-125 and cytoker-
atin 19, but these markers correlate better with tumor
burden or advanced stage [40].
We have taken a different approach, and focused on
known proteins that play a role in the development of
lung cancer. We included three proteins containing simi-
lar RNA-binding motifs, that we and others have shown
to be over-expressed in cancers and where antibodies to
these TAAs have been identified in cancer patients: IMP1
(insulin-like growth factor 2 mRNA binding protein),
IMP2/p62, and IMP3/Koc [12,19]. We also included the
tumor suppressor gene product p53 and oncogene c-myc,
proteins known to be aberrantly expressed in early lung
cancers. Survivin is an anti-apoptotic protein that we
have shown to be antigenic in cancer patients [23]. The
cell cycle proteins cyclin A, cyclin B1 (shown to be anti-
genic in several malignancies), cyclin D1 and CDK2 were
also included. Zhang and colleagues studied sera of 777
cancer patients with 20/84 (24 percent) of lung cancer
patients having one or more autoantibodies to this panel
of antigens [19].
The objective of this study was to distinguish bio-
marker measurements among five classifications based
on the CT scan: Non-smoking controls, no nodules, solid
nodules, ground glass opacities, and cancer. Based on the
nonsmoking and healthy smoker controls, patients with
lung cancer had increased levels of immune reactivity to
the TAAs. Smokers with benign solid nodules and smok-
ers with no nodules had equivalent lower levels of reac-
tivity. Smokers with GGOs, which may represent a
preneoplastic or neoplastic condition in some patients,
had an intermediate level of reactivity between patients
with cancer and smokers with normal CTs or benign
solid nodules. We found that reactivity to two tumor
associated antigens, c-myc and p62, correlated most
closely with the presence of either GGOs or lung cancer.
From these analyses, it appears that it is possible to dis-
tinguish cancer and ground glass opacity patients based
on their biomarker measurements with some measure of
certainty. Cyclin A, Cyclin D1, CDK2, and survivin
appear most often in models, irrespective of outcome.
However, this study is limited by small sample size, of
which only 22 patients had cancer and extreme bio-
marker measurements could not be repeated or validated.
Figure 1 Box plots of Age and Autoantibodies to TAAs by Classification Group. TAAs: p53, c-myc, IMP1, P62/IMP2, IMP3/KOC, Cyclin A, Cyclin B1, 
Cyclin D1, CDK2, Survivin. Classification Group: con-control, non-no nodule, sn-solid nodule, ggo-ground glass opacities, canc-cancer.Rom et al. BMC Cancer 2010, 10:234
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Table 4: Multiple Logistic Regression Models for cancer vs no cancer (no nodules, solid nodules, and ground glass 
opacities groups) based on log transformed biomarkers on 149 subjects with complete data.
A: All 
Biomarkers.
Estimate Std. Error z value Pr(>|z|)
(Intercept) 6.39 2.52 2.54 0.01
P53 -0.11 0.48 -0.22 0.82
C-myc 0.93 0.56 1.66 0.10
IMP1/Koc -0.21 0.56 -0.37 0.71
P62/IMP2 -0.30 0.49 -0.60 0.55
IMP3 0.14 0.67 0.21 0.84
Cyclin A 2.69 0.79 3.41 <0.01
Cyclin B1 -0.84 0.69 -1.22 0.22
Cyclin D1 -2.70 0.83 -3.27 <0.01
CDK2 1.32 0.67 1.95 0.05
Survivin 2.39 0.91 2.62 0.01
AIC 86.60
10 fold Cross 
Validation
91%
B: Stepwise 
Multiple Logistic 
Model.
Estimate Odds Ratio Std. Error z value Pr(>|z|)
(Intercept) 6.95 1043.15 2.25 3.09 <0.01
C-myc 0.80 2.22 0.53 1.53 0.13
Cyclin A 2.59 13.32 0.71 3.64 <0.01
Cyclin B1 -0.87 0.41 0.63 -1.38 0.17
C y c l i n  D 1 - 2 . 7 30 . 0 60 . 6 9 - 3 . 9 4 < 0 . 0 1Rom et al. BMC Cancer 2010, 10:234
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CDK2 1.27 3.56 0.60 2.11 0.04
Survivin 2.44 11.47 0.89 2.75 0.01
AIC: 79.40
10 fold Cross 
Validation
91%
Table 4: Multiple Logistic Regression Models for cancer vs no cancer (no nodules, solid nodules, and ground glass 
opacities groups) based on log transformed biomarkers on 149 subjects with complete data. (Continued)
Figure 2 ROC Curve Based on Stepwise Multiple Logistic Regression and Log Transformed Biomarkers to Classify Cancer/No Cancer (no 
nodules, solid nodules, and ground glass opacities groups).Rom et al. BMC Cancer 2010, 10:234
http://www.biomedcentral.com/1471-2407/10/234
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Persistent GGOs are more likely to represent preneo-
plastic or neoplastic lesions. Nakata and colleagues
reported that 100 percent of ground glass opacities ≤ 2
cm in size that persisted for at least three months were
found to be malignant or pre-malignant lesions on biopsy
or resection [41]. Many persistent GGOs are likely to be
adenocarcinoma, bronchoalveolar carcinoma, or atypical
adenomatous hyperplasia, and assessing these versus
benign nodules or smoker controls using autoantibodies
to TAAs is unique. Combinations of antibodies against
TAAs are most likely to achieve the necessary sensitivity
and specificity for early detection in CT scan screening
trials when small noncalcified solid or ground glass nod-
ules are discovered in the >8 mm size range. These pre-
diction models require validation in larger patient groups
with samples collected prospectively.
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